Management of peri-operative anti-thrombotic therapy

Anaesthesia

Volumn 70, Issue , 2015, Pages 58-67

  van Veen, J J ^a   Makris, M ^a,b  

^a Sheffield Haemophilia and Thrombosis Centre   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

COMPLICATION; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMAN; PERIOPERATIVE PERIOD; STENT; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBOSIS;

EID: 84925223895     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/ANAE.12900     Document Type: Review

References (92)

1. Spyropoulos AC. Pro: ‘‘Bridging anticoagulation is needed during warfarin interruption in patients who require elective sur-gery’’. Thrombosis and Haemostasis 2012; 108: 213–6.
2. Douketis JD. Contra: ‘‘Bridging anticoagulation is needed during warfarin interruption when patients require elective sur-gery’’. Thrombosis and Haemostasis 2012; 108: 210–2.
3. Douketis JD, Spyropoulos AC, Spencer F, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guide-lines. Chest 2012; 141(2 Suppl): e326S–50S.
4. Eijgenraam P, ten Cate H, Ten Cate-Hoek A. Safety and efficacy of bridging with low molecular weight heparins: a systematic review and partial meta-analysis. Current Pharmaceutical Design 2013; 19: 4014–23.
5. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Archives of Internal Medicine 2003; 163: 901–8.
6. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630–9.
7. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012; 126: 343–8.
8. Llau JV, Ferrandis R, Castillo J, et al. Management of direct action oral anticoagulants in the peri-operative period and invasive techniques. Revista Espanola de Anestesiologıa y Re-animacion 2012; 59: 321–30.
9. Sie P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommenda-tions of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Archives of Cardiovascular Diseases 2011; 104: 669–76.
10. Darvish-Kazem S, Gandhi M, Marcucci M, Douketis JD. Periop-erative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines. Chest 2013; 144: 1848– 56.
11. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagu-lation with warfarin – fourth edition. British Journal of Hae-matology 2011; 154: 311–24.
12. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287–92.
13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Journal of the American Medical Association 2001; 285: 2864–70.
14. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GYH. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thrombosis and Haemostasis 2012; 107: 1172–9.
15. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. British Medical Journal 2011; 342: d124.
16. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Anti-thrombotic and thrombolytic therapy for valvular disease: An-tithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e576S–600S.
17. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evi-dence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S–94S.
18. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during antico-agulant treatment in patients with cancer and venous throm-bosis. Blood 2002; 100: 3484–8.
19. Galli M. The antiphospholipid triangle. Journal of Thrombosis and Haemostasis 2010; 8: 234–6.
20. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis 2010; 8: 237–42.
21. Fyfe A, Tait RC. Antithrombin-α for the prophylaxis of venous thrombosis in congenital antithrombin deficiency. Expert Review of Hematology 2009; 2: 499–507.
22. Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thrombosis and Haemostasis 2009; 101: 806–12.
23. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635–41.
24. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. Journal of Thrombosis and Haemostasis 2010; 8: 884–90.
25. Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. British Medical Journal 2009; 339: b4583.
26. Tafur AJ, Wysokinski WE, McBane RD, et al. Cancer effect on periprocedural thromboembolism and bleeding in anticoagu-lated patients. Annals of Oncology 2012; 23: 1998–2005.
27. The Royal College of Ophthalmologists. Cataract Surgery Guidelines. 2010. http://www.rcophth.ac.uk/page.asp?sec tion=451(accessed 30/03/2014).
28. Perry DJ, Noakes TJC, Helliwell PS. Guidelines for the management of patients on oral anticoagulants requiring dental sur-gery. British Dental Journal 2007; 203: 389–93.
29. Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic proce-dures. Gut 2008; 57: 1322–9.
30. Birnie DH, Healey JS, Wells G, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. New England Journal of Medicine 2013; 368: 2084–93.
31. Feng L, Li Y, Li J, Yu B. Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices: a meta-analysis. Thrombosis and Haemostasis 2012; 108: 1124–31.
32. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal 2012; 33: 2719–47.
33. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 2010; 31: 2369–429.
34. Bajkin BV, Popovic SL, Selakovic SDJ. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. Journal of Oral and Maxillofacial Surgery 2009; 67: 990–5.
35. Dunn AS, Spyropoulos AC, Turpie AGG. Bridging therapy in patients on long-term oral anticoagulants who require sur-gery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). Journal of Thrombosis and Haemostasis 2007; 5: 2211–8.
36. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembo-lism with short-term interruption of warfarin therapy. Archives of Internal Medicine 2008; 168: 63–9.
37. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural antico-agulation regimen. Archives of Internal Medicine 2004; 164: 1319–26.
38. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecu-lar-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119: 2920–7.
39. Amorosi SL, Tsilimingras K, Thompson D, Fanikos J, Weinstein MC, Goldhaber SZ. Cost analysis of ‘‘bridging therapy’’ with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. American Journal of Cardiology 2004; 93: 509–11.
40. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004; 125: 1642–50.
41. Spyropoulos AC, Turpie AGG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagu-lants: the REGIMEN registry. Journal of Thrombosis and Hae-mostasis 2006; 4: 1246–52.
42. Attaya H, Shah ND, Wysokinski WE, Van Houten HK, Heit JA, McBane RD. Outcomes and total costs of outpatient vs. inpa-tient peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. International Journal of Cardiology 2013; 168: 5311–5.
43. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Annals of Internal Medicine 1995; 122: 40–2.
44. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evi-dence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S–453S.
45. Skeith L, Taylor J, Lazo-Langner A, Kovacs MJ. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study. Journal of Thrombosis and Haemostasis 2012; 10: 2298–304.
46. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. Journal of Thrombosis and Thrombolysis 2010; 29: 171–81.
47. Tafur aJ, McBane R, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. Journal of Thrombosis and Haemostasis 2012; 10: 261–7.
48. Turpie AGG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis 2012; 108: 876–86.
49. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625–51.
50. Ebertz F, Beyer-westendorf J, Gelbricht V, et al. Peri-interven-tional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. European Heart Journal 2014; 35: 1888–96.
51. Bayer plc. Rivaroxaban, Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/25586/SPC/Xarelto+20mg+film-coated+tablets/(accessed 26/04/2014).
52. Boehringel Ingelheim Limited. Dabigatran, Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/24839/SPC/Pradaxa+150+mg+hard+capsules/(accessed 26/04/2014).
53. Bristol-Myers Squibb-Pfizer. Apixaban, Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/27220/SPC/Eliquis+5+mg+film-coated+tablets/(accessed 26/04/2014).
54. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emer-gent reversal of oral thrombin and factor Xa inhibitors. American Journal of Hematology 2012; 87(Suppl 1): S141–5.
55. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. British Journal of Clinical Pharmacology 2010; 70: 703–12.
56. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metabolism and Disposition 2009; 37: 74–81.
57. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120: 2954–62.
58. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clinical Pharmacokinetics 2010; 49: 259– 68.
59. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemosta-sis. Journal of Thrombosis and Haemostasis 2013; 11: 760.
60. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. British Journal of Haematology 2012; 159: 427–9.
61. Arachchillage DRJ, Efthymiou M, Lawrie S, Machin SJ, Mackie IJ, Cohen H. Comparative sensitivity of commonly used throm-boplastins to ex vivo therapeutic rivaroxaban levels. Thrombosis and Haemostasis 2014; 112: 1–3.
62. Douxfils J, Chatelain C, Chatelain B, Dogne J-M, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thrombosis and Haemo-stasis 2013; 110: 283–94.
63. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabiga-tran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. Journal of Thrombosis and Haemo-stasis 2013; 11: 1493–502.
64. Van Veen JJ, Smith J, Kitchen S, Makris M. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. British Journal of Haematology 2013; 160: 859–61.
65. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology 2013; 160: 35–46.
66. Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. British Journal of Surgery 2014; 101: 742–9.
67. Ferrandis R, Castillo J, de Andres J, et al. The perioperative management of new direct oral anticoagulants: a question without answers. Thrombosis and Haemostasis 2013; 110: 515–22.
68. Makris M, Malhotra S, Nicholls B, Popat M, Swales H, Wood P. Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain & Ireland The Obstetric Anaesthetists’ Association Regional Anaesthesia UK. Anaesthesia 2013; 68: 966–72.
69. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacody-namic considerations. Clinical Pharmacokinetics 2004; 43: 963–81.
70. Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multi-centre, randomized, blinded, placebo-controlled, STRATAGEM trial. British Journal of Anaesthesia 2011; 107: 899–910.
71. Oscarsson A, Gupta A, Fredrikson M, et al. To continue or dis-continue aspirin in the perioperative period: a randomized, controlled clinical trial. British Journal of Anaesthesia 2010; 104: 305–12.
72. Group PEP (PEP) trial C. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295–302.
73. Burger W, Chemnitius J-M, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. Journal of Internal Medicine 2005; 257: 399–414.
74. Sun JCJ, Whitlock R, Cheng J, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. European Heart Journal 2008; 29: 1057–71.
75. Alghamdi AA, Moussa F, Fremes SE. Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and meta-analysis. Journal of Cardiac Surgery 2007; 22: 247–56.
76. Mangano DT. Aspirin and mortality from coronary bypass sur-gery. New England Journal of Medicine 2002; 347: 1309–17.
77. Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 2005; 112: I286–92.
78. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Annals of Thoracic Surgery 2000; 70: 1986–90.
79. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001; 345: 494–502.
80. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with dif-ferent combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967–74.
81. Ernst A, Eberhardt R, Wahidi M, Becker HD, Herth FJF. Effect of routine clopidogrel use on bleeding complications after trans-bronchial biopsy in humans. Chest 2006; 129: 734–7.
82. Korte W, Cattaneo M, Chassot P-G, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thrombosis and Haemostasis 2011; 105: 743–9.
83. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. Journal of the American College of Cardiology 2006; 47: 2112–5.
84. Abualsaud AO, Eisenberg MJ. Perioperative management of patients with drug-eluting stents. Journal of the American College of Cardiology Cardiovascular Interventions 2010; 3: 131–42.
85. Cruden NLM, Harding SA, Flapan AD, et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circulation Cardiovascular Interventions 2010; 3: 236–42.
86. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Journal of the American Medical Association 2005; 293: 2126–30.
87. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predic-tors, and outcomes of premature discontinuation of thieno-pyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006; 113: 2803–9.
88. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119: 1634–42.
89. Chassot P-G, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. British Journal of Anaesthesia 2007; 99: 316–28.
90. Thiele T, Sumnig A, Hron G, et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. Journal of Thrombosis and Hae-mostasis 2012; 10: 968–71.
91. Skeith L, Lazo-Langner A, Kovacs MJ. The equipoise of periop-erative anticoagulation management: a Canadian cross-sec-tional survey. Journal of Thrombosis and Thrombolysis 2014; 37: 411–3.
92. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. European Journal of Clinical Pharmacology 2005; 61: 873–80.